Spero Therapeutics (STU:2HA) Price-to-Tangible-Book : 3.79 (As of Jul. 16, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics Price-to-Tangible-Book?

As of today (2025-07-16), Spero Therapeutics's share price is €2.125. Spero Therapeutics's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was €0.56. Hence, Spero Therapeutics's Price to Tangible Book Ratio of today is 3.79.

The historical rank and industry rank for Spero Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

STU:2HA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72 Med: 1.98 Max: 5.88
Current: 3.94

During the past 10 years, Spero Therapeutics's highest Price to Tangible Book Ratio was 5.88. The lowest was 0.72. And the median was 1.98.

STU:2HA's Price-to-Tangible-Book is ranked worse than
62.6% of 1198 companies
in the Biotechnology industry
Industry Median: 3.045 vs STU:2HA: 3.94

A closely related ratio is called PB Ratio. As of today, Spero Therapeutics's share price is €2.125. Spero Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2025 was €0.56. Hence, Spero Therapeutics's P/B Ratio of today is 3.79.

Spero Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Spero Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Price-to-Tangible-Book Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.42

5.51

1.15

0.70

1.19

Spero Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Tangible-Book	Get a 7-Day Free Trial															0.96	0.88	1.10	1.19	1.17

Competitive Comparison of Spero Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Spero Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Spero Therapeutics Price-to-Tangible-Book Calculation

Spero Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2025 )
	=	2.125	/	0.56
	=	3.79

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Spero Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SPRO:USA 2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines